| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 08/04/2026 | ±3.1% | +2.8% | over-priced |
| 05/05/2026 | ±2.5% | +0.7% | over-priced |
| 11/03/2025 | ±1.8% | -0.2% | over-priced |
| 05/05/2025 | ±2.9% | -0.5% | over-priced |
| 11/04/2024 | ±1.6% | -0.6% | over-priced |
| 08/05/2024 | ±3.2% | -3.9% | under-priced |
| 05/03/2024 | ±1.5% | +1.1% | over-priced |
| 11/03/2023 | ±2.1% | +3.8% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q2 FY2026 | $3.46 | $21.3B | $5.7B |
| Q1 FY2026 | $3.43 | $20.6B | $5.6B |
| Q4 FY2025 | $2.68 | $17.9B | $4.4B |
| Q3 FY2025 | $2.80 | $18.2B | $4.7B |
Morgan Stanley (MS) reports in 121 days, with the next report estimated for 01/11/2027. Across the last 8 reports, options priced an average ±2.4% earnings move while the stock actually moved 1.7% on average — the market has systematically over-priced MS's earnings risk. Fundamentals into the print: EPS up 33.1% year-over-year, revenue up 20.3%. QuantLogix's live 5-factor engine currently reads MS as a neutral at 50/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →